A Phase 1b Multiple Ascending-dose Study of itolizumab (EQ001) in Subjects With Systemic
Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis
The EQUALISE study is a Phase 1b study to evaluate the safety and tolerability of itolizumab
in patients with lupus and lupus nephritis. The study will have two cohorts studied over
three defined periods – screening, treatment, and follow-up. The treatment period for
patients with systemic lupus erythematosus in Type A Cohort was 4 weeks in duration and is now complete.
Treatment for patients with active proliferative lupus nephritis in Type B Cohort is 24
weeks in duration and is currently enrolling. The trial design was informed by members of the lupus community,
including leading clinical and scientific experts in the lupus field, the Lupus Research
Alliance, and patients living with lupus and/or lupus nephritis.